Neuronetics (STIM) Stock Price, News & Analysis

Company Overview

Neuronetics, Inc. is a commercial‐stage medical technology company that develops and markets non-invasive neuromodulation therapies for psychiatric and neurological disorders. The company’s flagship product, the NeuroStar Advanced Therapy System, uses repetitive transcranial magnetic stimulation (rTMS) to deliver targeted magnetic pulses to areas of the brain implicated in major depressive disorder (MDD). NeuroStar Advanced Therapy has received U.S. Food and Drug Administration clearance for the treatment of adults with treatment-resistant depression and is supported by a growing body of clinical evidence demonstrating its safety and efficacy.

Founded in 2003 and headquartered in Malvern, Pennsylvania, Neuronetics focuses on advancing clinical care through innovation in neurostimulation. The company’s platform is designed for use in outpatient clinics, hospitals and psychiatry practices across the United States. Neuronetics maintains a specialized field sales force and collaborates with key channel partners to support physician training, patient education and therapy delivery. In addition to its commercial activities, the company continues to explore new indications and protocol optimizations to expand its therapeutic offerings.

Guided by a leadership team with deep experience in medical devices and neuroscience, Neuronetics strives to improve patient outcomes through research, regulatory engagement and post-market data collection. The company’s ongoing efforts include refining device features, enhancing treatment compliance and evaluating the use of its technology in other neuropsychiatric conditions. Neuronetics is publicly traded on the Nasdaq under the symbol STIM.

Key Stats

• Today's Range: $2.99 to $3.15
• 50-Day Range: $1.20 to $3.30
• 52-Week Range: $0.80 to $3.71
• Volume: 1.01 million shs
• Average Volume: 3.07 million shs
• Market Capitalization: $228.60 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $4.50
• Consensus Rating: Moderate Buy

Neuronetics Stock Analysis - MarketRank™

Neuronetics scored higher than 79% of companies evaluated by MarketBeat, and ranked 121st out of 914 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.9 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Neuronetics has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on no strong buy ratings, 3 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

Neuronetics has a consensus price target of $4.50, representing about 50.0% upside from its current price of $3.00.

Amount of Analyst Coverage

Neuronetics has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Neuronetics is -6.82, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Neuronetics is -6.82, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Neuronetics has a P/B Ratio of 10.71. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

14.63% of the float of Neuronetics has been sold short.

Short Interest Ratio / Days to Cover

Neuronetics has a short interest ratio ("days to cover") of 3.44, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Neuronetics has recently decreased by 0.48%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Neuronetics does not currently pay a dividend.

Dividend Growth

Neuronetics does not have a long track record of dividend growth.

News and Social Media

• Score: 4.5 / 5
• News Sentiment: 1.20

News Sentiment

Neuronetics has a news sentiment score of 1.20. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.61 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for Neuronetics this week, compared to 3 articles on an average week.

Search Interest

7 people have searched for STIM on MarketBeat in the last 30 days. This is an increase of 17% compared to the previous 30 days.

MarketBeat Follows

2 people have added Neuronetics to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 3.8 / 5
• Insider Trading: Acquiring Shares

Net Insider Buying

Over the last three months, insiders have purchased a net $44,240.00 in company stock, which represents 0.0194% of the company's market cap.

Insider Buying vs. Insider Selling

In the past three months, Neuronetics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $44,240.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

8.40% of the stock of Neuronetics is held by insiders.

Percentage Held by Institutions

53.59% of the stock of Neuronetics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/11/2026
• Today: 8/21/2026
• Next Earnings (Estimated): 11/03/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Healthcare Equipment & Supplies
• Sub-Industry: Healthcare Equipment
• Current Symbol: NASDAQ:STIM
• CIK: 1227636
• Web: www.neurostar.com
• Phone: (610) 640-4202
• Fax: 610-640-4206
• Employees: 180
• Year Founded: 2003

Price Target and Rating

• Average Price Target for Neuronetics: $4.50
• High Price Target: $6.00
• Low Price Target: $3.00
• Potential Upside/Downside: +50.0%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.50
• Research Coverage: 4 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.44)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$39 million
• Net Margins: -19.62%
• Pretax Margin: -19.89%
• Return on Equity: -125.11%
• Return on Assets: -22.15%

Debt

• Debt-to-Equity Ratio: 2.84
• Current Ratio: 1.88
• Quick Ratio: 1.69

Sales & Book Value

• Annual Sales: $149.16 million
• Price / Sales: 1.53
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.28 per share
• Price / Book: 10.71

Miscellaneous

• Outstanding Shares: 76,200,000
• Free Float: 69,796,000
• Market Cap: $228.60 million
• Optionable: Optionable
• Beta: 1.03